Nov 09, 2009 Press Release for Alnylam

Alnylam to Webcast R&D Day on Thursday, November 12, 2009

Nov 09, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2009-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com.

Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. In addition, Alnylam will host two guest speakers:

• Professor Allan R. Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus (RSV) infection in the lung transplant patient population; and,
• Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School Royal Free Hospital, will discuss transthyretin (TTR)-mediated amyloidosis.

Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET at the Loews Regency Hotel in New York City. An audio replay of the event will be posted on the Alnylam website approximately three hours after the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko Kirin. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam established “RNAi 2010” in January 2008 which includes the company’s plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA-based therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Source: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.
Cynthia Clayton (Investors)
617-551-8207
or
Kathryn Morris (Media)
Yates Public Relations
845-635-9828